March 24, 2022 -- Artificial intelligence-powered spatial biology company Nucleai closed a $33 million series B financing round, which it will use to advance its spatial biology platform for drug research, development, and diagnostics.
The company said it plans to use the new funding to further develop its platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations, which are applying Nucleai's technology throughout translational research, clinical trials, and novel applications for drug discovery.
The funding round was jointly led by Section 32 and Sanofi Ventures. Existing investors, including Debiopharm, Fosun RZ Capital, Vertex Ventures, and Grove Ventures, participated in this round, the company reported.
Copyright © 2022 scienceboard.net